Fulcrum Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Fulcrum Therapeutics, Inc. on June 9, 2021. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Class II Directors: Stockholders elected James Collins, James Geraghty, and Bryan Stuart to three-year terms expiring in 2024.
- James Collins: 20,712,181 votes For; 4,327,526 votes Withheld.
- James Geraghty: 18,119,917 votes For; 6,919,790 votes Withheld.
- Bryan Stuart: 24,937,075 votes For; 102,632 votes Withheld.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Results: 28,530,785 votes For; 0 votes Against; 20,968 votes Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes withheld for directors James Collins and James Geraghty.
- Confirm the specific responsibilities and tenure of the newly elected Class II directors.
- Review the full proxy statement for details on the audit committee's rationale for selecting Ernst & Young LLP.